Fig. 4From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft ModelAnti-tumor activity of IL-13 cytotoxin in HN12 tumor xenografted mice. Male and female mice bearing SC tumors were treated with 100 µg/kg/day IV (A) or 200 µg/kg/day CI (B) of IL13-PE38QQR from day 4 to day 10 (7 days) (n = 6). Bars represent the SD; CR, complete response.Back to article page